Altimmune Statistics
Share Statistics
Altimmune has 77.01M
shares outstanding. The number of shares has increased by 8.62%
in one year.
| Shares Outstanding | 77.01M |
| Shares Change (YoY) | 8.62% |
| Shares Change (QoQ) | 8.28% |
| Owned by Institutions (%) | 56.91% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 641 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 22.58M, so 31.74% of the outstanding
shares have been sold short.
| Short Interest | 22.58M |
| Short % of Shares Out | 31.74% |
| Short % of Float | 31.83% |
| Short Ratio (days to cover) | 13.78 |
Valuation Ratios
The PE ratio is -5.39 and the forward
PE ratio is -3.51.
Altimmune's PEG ratio is
0.28.
| PE Ratio | -5.39 |
| Forward PE | -3.51 |
| PS Ratio | 25596.73 |
| Forward PS | 0.8 |
| PB Ratio | 4.14 |
| P/FCF Ratio | -6.41 |
| PEG Ratio | 0.28 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Altimmune.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.11,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 13.11 |
| Quick Ratio | 13.11 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | -11463.56 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $338.98 |
| Profits Per Employee | $-1,611,169.49 |
| Employee Count | 59 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -25.96% in the
last 52 weeks. The beta is 1.11, so Altimmune's
price volatility has been higher than the market average.
| Beta | 1.11 |
| 52-Week Price Change | -25.96% |
| 50-Day Moving Average | 5.19 |
| 200-Day Moving Average | 6.62 |
| Relative Strength Index (RSI) | 57.44 |
| Average Volume (20 Days) | 2,587,351 |
Income Statement
In the last 12 months, Altimmune had revenue of 20K
and earned -95.06M
in profits. Earnings per share was -1.34.
| Revenue | 20K |
| Gross Profit | -218K |
| Operating Income | -103.17M |
| Net Income | -95.06M |
| EBITDA | -94.81M |
| EBIT | -95.05M |
| Earnings Per Share (EPS) | -1.34 |
Full Income StatementBalance Sheet
The company has 36.93M in cash and 1.68M in
debt, giving a net cash position of 35.24M.
| Cash & Cash Equivalents | 36.93M |
| Total Debt | 1.68M |
| Net Cash | 35.24M |
| Retained Earnings | -561.39M |
| Total Assets | 139.31M |
| Working Capital | 126.79M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -79.85M
and capital expenditures 0, giving a free cash flow of -79.85M.
| Operating Cash Flow | -79.85M |
| Capital Expenditures | n/a |
| Free Cash Flow | -79.85M |
| FCF Per Share | -1.12 |
Full Cash Flow StatementMargins
Gross margin is -1090%, with operating and profit margins of -515860% and -475295%.
| Gross Margin | -1090% |
| Operating Margin | -515860% |
| Pretax Margin | -475295% |
| Profit Margin | -475295% |
| EBITDA Margin | -474060% |
| EBIT Margin | -515860% |
| FCF Margin | -399240% |
